aTyr Pharma Inc. (ATYR) Cash Flow Statement Analysis - Operating Cash Flow, CapEx & Free Cash Flow - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    aTyr Pharma Inc.

    NASDAQ: ATYR · Real-Time Price · USD
    0.84
    -0.05 (-5.97%)
    At close: Sep 26, 2025, 3:59 PM
    0.85
    0.92%
    After-hours: Sep 26, 2025, 07:59 PM EDT

    aTyr Pharma Cash Flow Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Net Income
    		 -64.02M -50.39M -45.34M -33.77M
    Depreciation & Amortization
    		 1.54M 2.74M 1.7M 1.3M
    Stock-Based Compensation
    		 2.99M 2.6M 2.15M 1.61M
    Other Working Capital
    		 -5.98M 2.7M 4.35M -4.24M
    Other Non-Cash Items
    		 -2.71M -3.19M 436K 363K
    Deferred Income Tax
    		 n/a n/a n/a n/a
    Change in Working Capital
    		 -6.92M 15.01M -833K -2.59M
    Operating Cash Flow
    		 -69.12M -33.22M -41.89M -33.08M
    Capital Expenditures
    		 -65K -4.21M -1.64M -192K
    Cash Acquisitions
    		 7K n/a 179K 50K
    Purchase of Investments
    		 -69.1M -106.98M -42.12M -126.51M
    Sales Maturities Of Investments
    		 86.39M 91.05M 90.83M 35.08M
    Other Investing Acitivies
    		 n/a 15K n/a n/a
    Investing Cash Flow
    		 17.23M -20.13M 47.24M -91.57M
    Debt Repayment
    		 -497K -394K -66K n/a
    Common Stock Repurchased
    		 n/a n/a n/a n/a
    Dividend Paid
    		 n/a n/a n/a n/a
    Other Financial Acitivies
    		 100K 105K 45K 73K
    Financial Cash Flow
    		 39.86M 66.23M 5.45M 110.03M
    Net Cash Flow
    		 -12.02M 12.88M 10.81M -14.62M
    Free Cash Flow
    		 -69.18M -37.44M -43.53M -33.27M

    Add to Watchlist